Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Julie Nonnekens

Showing results (11-20 of 54) with videos related to

Pageof 6
Sort By:
European Journal of Nuclear Medicine and Molecular Imaging|February 27, 2025
Recommendations for reporting preclinical radiobiological studies in targeted radionuclide therapyFilipa Mendes, Samantha Y A Terry, Diana Spiegelberg, et al.
Prostate Cancer and Prostatic Diseases|June 15, 2019
Role of the DNA damage response in prostate cancer formation, progression and treatmentWenhao Zhang, Dik C van Gent, Luca Incrocci, et al.
Prostate Cancer and Prostatic Diseases|July 19, 2019
Correction to: Role of the DNA damage response in prostate cancer formation, progression and treatmentWenhao Zhang, Dik C van Gent, Luca Incrocci, et al.
Human Molecular Genetics|April 9, 2013
Mutations in TFIIH causing trichothiodystrophy are responsible for defects in ribosomal RNA production and processingJulie Nonnekens, Jorge Perez-Fernandez, Arjan F Theil, et al.
EJNMMI Research|August 13, 2024
Enhancing [<sup>177</sup>Lu]Lu-DOTA-TATE therapeutic efficacy in vitro by combining it with metronomic chemotherapeuticsJordan Cheng, Joke Zink, Edward O'Neill, et al.
Cancers|December 11, 2022
A Clinical Guide to Peptide Receptor Radionuclide Therapy with <sup>177</sup>Lu-DOTATATE in Neuroendocrine Tumor PatientsMorticia N Becx, Noémie S Minczeles, Tessa Brabander, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 13, 2026
Targeted Radionuclide Therapy: Current Landscape and Combination Approaches to Improve Oncology OutcomesJulie Nonnekens, Lauren A Byers, Aman Chauhan, et al.
Physica Medica : PM : an International Journal Devoted to the Applications of Physics to Medicine and Biology : Official Journal of the Italian Association of Biomedical Physics (AIFB)|March 4, 2022
Therapeutic efficacy of heterogeneously distributed radiolabelled peptides: Influence of radionuclide choiceGiulia Tamborino, Julie Nonnekens, Lara Struelens, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|May 22, 2025
Establishing In Vitro Dosimetric Models and Dose-Effect Relationships for <sup>177</sup>Lu-DOTATATE in Neuroendocrine TumorsGiulia Tamborino, Pleun Engbers, Tijmen H de Wolf, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 10, 2021
Dosimetric Evaluation of the Effect of Receptor Heterogeneity on the Therapeutic Efficacy of Peptide Receptor Radionuclide Therapy: Correlation with DNA Damage Induction and In Vivo SurvivalGiulia Tamborino, Julie Nonnekens, Marijke De Saint-Hubert, et al.
Pageof 6

Showing results (11-20 of 54) with videos related to

Sort By:
Pageof 6
European Journal of Nuclear Medicine and Molecular Imaging|February 27, 2025
Recommendations for reporting preclinical radiobiological studies in targeted radionuclide therapyFilipa Mendes, Samantha Y A Terry, Diana Spiegelberg, et al.
Prostate Cancer and Prostatic Diseases|June 15, 2019
Role of the DNA damage response in prostate cancer formation, progression and treatmentWenhao Zhang, Dik C van Gent, Luca Incrocci, et al.
Prostate Cancer and Prostatic Diseases|July 19, 2019
Correction to: Role of the DNA damage response in prostate cancer formation, progression and treatmentWenhao Zhang, Dik C van Gent, Luca Incrocci, et al.
Human Molecular Genetics|April 9, 2013
Mutations in TFIIH causing trichothiodystrophy are responsible for defects in ribosomal RNA production and processingJulie Nonnekens, Jorge Perez-Fernandez, Arjan F Theil, et al.
EJNMMI Research|August 13, 2024
Enhancing [<sup>177</sup>Lu]Lu-DOTA-TATE therapeutic efficacy in vitro by combining it with metronomic chemotherapeuticsJordan Cheng, Joke Zink, Edward O'Neill, et al.
Cancers|December 11, 2022
A Clinical Guide to Peptide Receptor Radionuclide Therapy with <sup>177</sup>Lu-DOTATATE in Neuroendocrine Tumor PatientsMorticia N Becx, Noémie S Minczeles, Tessa Brabander, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 13, 2026
Targeted Radionuclide Therapy: Current Landscape and Combination Approaches to Improve Oncology OutcomesJulie Nonnekens, Lauren A Byers, Aman Chauhan, et al.
Physica Medica : PM : an International Journal Devoted to the Applications of Physics to Medicine and Biology : Official Journal of the Italian Association of Biomedical Physics (AIFB)|March 4, 2022
Therapeutic efficacy of heterogeneously distributed radiolabelled peptides: Influence of radionuclide choiceGiulia Tamborino, Julie Nonnekens, Lara Struelens, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|May 22, 2025
Establishing In Vitro Dosimetric Models and Dose-Effect Relationships for <sup>177</sup>Lu-DOTATATE in Neuroendocrine TumorsGiulia Tamborino, Pleun Engbers, Tijmen H de Wolf, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 10, 2021
Dosimetric Evaluation of the Effect of Receptor Heterogeneity on the Therapeutic Efficacy of Peptide Receptor Radionuclide Therapy: Correlation with DNA Damage Induction and In Vivo SurvivalGiulia Tamborino, Julie Nonnekens, Marijke De Saint-Hubert, et al.
Pageof 6